Pathogenesis, Diagnosis and Treatment of Ascites in Cirrhosis

Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition

Volumn , Issue , 2008, Pages 666-710

  Arroyo, Vicente ^a   Terra, Carlos ^b   Ruiz del Arbol, Luis ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Cirrhotic ascites; Echography; Hepatic sinusoids; Pathogenesis; Peritoneal cavity

Indexed keywords

EID: 84889285136     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470691861.ch7e     Document Type: Chapter

References (279)

1. Berner C, Davis JS, Riggs S et al. (1964) Diagnostic probabilities in patients with conspicuous ascites. Arch Intern Med 113, 687-690.
2. Lawson JD, Weissbein AS (1959) The puddle sign-an aid in the diagnosis of minimal ascites. N Engl J Med 260, 652-654.
3. Cattau EL, Benjamin SB, Knuff TE et al. (1982) The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 247, 1164-1166.
4. Branney SW, Wolfe RE, Moore EE et al. (1995) Quantitative sensitivity of ultrasound in detecting free intraperitoneal fluid. J Trauma Injury Infect Crit Care 39, 375-380.
5. Huning R (1973) Ultrasonic diagnosis of Wilms tumor. Fortschritte Gebiete Rontgenstrahl Nuklearmed 158-159.
6. Wall SD, Hricak H, Bailey GD et al. (1986) MR imaging of pathological abdominal fluid collections. J Comp Assist Tomogr 10, 746-750.
7. Proto AV, Lane EJ (1976) Visualization of differences in soft-tissue densities-liver in ascites. Radiology 121, 19-23.
8. Steinkampf MP, Blackwell RE, Younger JB (1991) Visualization of free peritoneal fluid with transvaginal sonography-a preliminary study. J Reprod Med 36, 729-730.
9. Edell SL, Gefter WB (1979) Ultrasonic differentiation of types of ascitic fluid. Am J Roentgenol 133, 111-114.
10. Kedar RP, Shah PP, Shivde RS et al. (1994) Sonographic findings in gastroenterology and peritoneal tuberculosis. Clin Radiol 49, 24-29.
11. Runyon BA, Montano AA, Akriviadis EA et al. (1992) The serum ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 117, 215-220.
12. Wilson JAP, Suguitan EA, Cassidy WA et al. (1979) Characteristics of ascitic fluid in the alcoholic cirrhotic. Dig Dis Sci 24, 645-648.
13. Sampline RE, Iber FL (1974) High protein ascites in patients with uncomplicated hepatic cirrhosis. Am J Med Sci 267, 275-279.
14. Hoefs JC (1983) Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med 102, 260-273.
15. Henriksen JH (1983) Permselectivity of the liver blood lymph (ascitic fluid) barrier to macromolecules in decompensated cirrhosis-relation to calculated pore size. Clin Physiol 3, 163-171.
16. Henriksen JH, Lassen NA, Parving HH et al. (1980) Filtration as the main transport mechanism of protein exchange between plasma and the peritoneal-cavity in hepatic cirrhosis. Scand J Clin Lab Invest 40, 503-513.
17. Runyon BA, Vanepps DE (1986) Diuresis of cirrhotic ascites increases its opsonic activity and may help prevent spontaneous bacterial peritonitis. Hepatology 6, 396-399.
18. Fromkes JJ, Thomas FB, Mekhjian HS et al. (1977) Antimicrobial activity of human ascitic fluid. Gastroenterology 73, 668-672.
19. Simberkoff MS, Moldover NH, Weiss G (1978) Bactericidal and opsonic activity of cirrhotic ascites and nonascitic peritoneal fluid. J Lab Clin Med 91, 831-839.
20. Runyon BA, Morrissey RL, Hoefs JC et al. (1985) Opsonic activity of human ascitic fluid-a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 5, 634-637.
21. Such J, Guarner C, Enriquez J et al. (1988) Low C-3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 6, 80-84.
22. Barmeir S, Lerner E, Conn HO (1979) Analysis of ascitic fluid in cirrhosis. Dig Dis Sci 24, 136-144.
23. Conn HO, Fessel JM (1971) Spontaneous bacterial peritonitis in cirrhosis-variations on a theme. Medicine 50, 161-197.
24. Hoefs JC, Runyon BA (1985) Spontaneous bacterial peritonitis. Disease-A-Month 31, 1-48.
25. Gitlin N, Stauffer JL, Silvestri RC (1982) The Ph of ascitic fluid in the diagnosis of spontaneous bacterial peritonitis in alcoholic cirrhosis. Hepatology 2, 408-411.
26. Stassen WN, McCullough AJ, Bacon BR et al. (1986) Immediate diagnostic-criteria for bacterial-infection of ascitic fluid-evaluation of ascitic fluid polymorphonuclear leukocyte count, Ph, and lactate concentration, alone and in combination. Gastroenterology 90, 1247-1254.
27. Garciatsao G, Conn HO, Lerner E (1985) The diagnosis of bacterial peritonitis-comparison of Ph, lactate concentration and leukocyte count. Hepatology 5, 91-96.
28. Hoefs JC (1981) Increase in ascites white blood cell and protein concentrations during diuresis in patients with chronic liver disease. Hepatology 1, 249-254.
29. Desitter L, Rector WG (1984) The significance of bloody ascites in patients with cirrhosis. Am J Gastroenterol 79, 136-138.
30. Dumont AE, Mulholland JH (1960) Flow rate and composition of thoracic-duct lymph in patients with cirrhosis. N Engl J Med 263, 471-474.
31. Buo L, Karlsrud TS, Dyrhaug G et al. (1995) The fibrinolytic system in human ascites. Scand J Gastroenterol 30, 1101-1107.
32. Hoefs J, Barnes T, Halle P (1981) Intraperitoneal coagulation in chronic liver disease ascites. Dig Dis Sci 26, 518-522.
33. Wilkinson SP, Henderson J, Davidson AR et al. (1975) Ascites reinfusion using rhodiascit apparatus-clinical experience and coagulation abnormalities. Postgrad Med J 51, 583-587.
34. Leveen HH, Ahmed N, Hutto RB et al. (1987) Coagulopathy post peritoneovenous shunt. Ann Surg 205, 305-311.
35. Bac DJ, Pruimboom WM, Mulder PGH et al. (1995) High interleukin-6 production within the peritoneal-cavity in decompensated cirrhosis and malignancy-related ascites. Liver 15, 265-270.
36. Zeni F, Tardy B, Vindimian M et al. (1993) High levels of tumor necrosis factor alpha and interleukin-6 in the ascitic fluid of cirrhotic patients with spontaneous bacterial peritonitis. Clin Infect Dis 17, 218-223.
37. Navasa M, Follo A, Filella X et al. (1998) Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 27, 1227-1232.
38. Cejudo P, Jimenez W, Ros J et al. (2001) Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 34, 184A.
39. Giannini E, Romagnoli P, Tenconi GL et al. (2004) High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: relationship with TNF-alpha levels. Dig Dis Sci 49, 275-280.
40. Runyon BA, Hoefs JC, Morgan TR (1988) Ascitic fluid analysis in malignancy-related ascites. Hepatology 8, 1104-1109.
41. Rector WG, Reynolds TB (1984) Superiority of the serum ascites albumin difference over the ascites total protein concentration in separation of transudative and exudative ascites. Am J Med 77, 83-85.
42. Garcia LW, Ducatman BS, Wang HH (1994) The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol 7, 665-668.
43. Prieto M, Gomezlechon MJ, Hoyos M et al. (1988) Diagnosis of malignant ascites-comparison of ascitic fibronectin, cholesterol, and serum-ascites albumin difference. Dig Dis Sci 33, 833-838.
44. Gerbes AL, Jungst D, Xie YN et al. (1991) Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites-proposal of a diagnostic sequence. Cancer 68, 1808-1814.
45. Castaldo G, Oriani G, Cimino L et al. (1994) Total discrimination of peritoneal malignant ascites from cirrhosis-associated and hepatocarcinoma-associated ascites by assays of ascitic cholesterol and lactate dehydrogenase. Clin Chem 40, 478-483.
46. Hafter R, Klaubert W, Gollwitzer R et al. (1984) Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Thromb Res 35, 53-64.
47. Gerbes AL, Hoermann R, Mann K et al. (1996) Human chorionic gonadotropin-beta in the differentiation of malignancy-related and nonmalignant ascites. Digestion 57, 113-117.
48. Lee CM, Changchien CS, Shyu WC et al. (1992) Serum ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites. Cancer 70, 2057-2060.
49. Chu CM, Lin SM, Peng SM et al. (1994) The role of laparoscopy in the evaluation of ascites of unknown origin. Gastrointest Endosc 40, 285-289.
50. Rector WG (1984) Spontaneous chylous ascites of cirrhosis. J Clin Gastroenterol 6, 369-372.
51. Press OW, Press NO, Kaufman SD (1982) Evaluation and management of chylous ascites. Ann Intern Med 96, 358-364.
52. Malagela JR, Iber FL, Linschee WG (1974) Origin of fat in chylous ascites of patients with liver cirrhosis. Gastroenterology 67, 878-886.
53. Maywood BT, Goldstein L, Busuttil RW (1978) Chylous ascites after a Warren shunt. Am J Surg 135, 700-702.
54. Lingenfelser T, Zak J, Marks IN et al. (1993) Abdominal tuberculosis-still a potentially lethal disease. Am J Gastroenterol 88, 744-750.
55. Lundstedt C, Nyman R, Brismar J et al. (1996) Imaging of tuberculosis. 2. Abdominal manifestations in 112 patients. Acta Radiol 37, 489-495.
56. Shakil AO, Korula J, Kanel GC et al. (1996) Diagnostic features of tuberculous peritonitis in the absence and presence of chronic liver disease: a case control study. Am J Med 100, 179-185.
57. Martinezvazquez JM, Ocana I, Ribera E et al. (1986) Adenosine deaminase activity in the diagnosis of tuberculous peritonitis. Gut 27, 1049-1053.
58. Hillebrand DJ, Runyon BA, Yasmineh WG et al. (1996) Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology 24, 1408-1412.
59. Wolfe JHN, Behn AR, Jackson BT (1979) Tuberculous peritonitis and role of diagnostic laparoscopy. Lancet 1, 852-853.
60. Delope CR, Joglar GSM, Romero FP (1982) Laparoscopic diagnosis of tuberculous ascites. Endoscopy 14, 178-179.
61. Bhargava DK, Shriniwa S, Chopra P et al. (1992) Peritoneal tuberculosis-laparoscopic patterns and its diagnostic accuracy. Am J Gastroenterol 87, 109-112.
62. Holmes EC, Eggleston JC (1972) Starch granulomatous peritonitis. Surgery 71, 85-90.
63. Schwake L, von Herbay A, Junghanss T et al. (2003) Peritoneal tuberculosis with negative polymerase chain reaction results: report of two cases. Scand J Gastroenterol 38, 221-224.
64. Gamboa F, Dominguez J, Padilla E et al. (1998) Rapid diagnosis of extrapulmonary tuberculosis by ligase chain reaction amplification. J Clin Microbiol 36, 1324-1329.
65. Runyon BA (1988) Cardiac ascites-a characterization. J Clin Gastroenterol 10, 410-412.
66. Ackerman NB, Sillin LF, Suresh K (1985) Consequences of intraperitoneal bile-bile ascites versus bile peritonitis. Am J Surg 149, 244-246.
67. Sankaran S, Walt AJ (1976) Pancreatic ascites-recognition and management. Arch Surg 111, 430-434.
68. Maringhini A, Ciambra M, Patti R et al. (1996) Ascites, pleural, and pericardial effusions in acute pancreatitis-a prospective study of incidence, natural history, and prognostic role. Dig Dis Sci 41, 848-852.
69. Boyer TD, Kahn AM, Reynolds TB (1978) Diagnostic value of ascitic fluid lactic-dehydrogenase, protein, and WBC levels. Arch Intern Med 138, 1103-1105.
70. Hammond TC, Takiyyuddin MA (1994) Nephrogenic ascites-a poorly understood syndrome. J Am Soc Nephrol 5, 1173-1177.
71. Balasch J, Arroyo V, Fabregues F et al. (1994) Neurohormonal and hemodynamic-changes in severe cases of the ovarian hyperstimulation syndrome. Ann Intern Med 121, 27-33.
72. Lieberman F, Hidemura R, Peters RL et al. (1966) Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med 64, 341-351.
73. Lieberman F, Peters RL (1970) Cirrhotic hydrothorax. Further evidence that an acquired diaphragmatic defect is at fault. Arch Intern Med 125, 114.
74. Singer JA, Kaplan MM, Katz RL (1977) Cirrhotic pleural effusion in absence of ascites. Gastroenterology 73, 575-577.
75. Xiol X, Castellvi JM, Guardiola J et al. (1996) Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology 23, 719-723.
76. Mouroux J, Perrin C, Venissac N et al. (1996) Management of pleural effusion of cirrhotic origin. Chest 109, 1093-1096.
77. Witte MH, Witte CL, Dumont AE (1981) Estimated net transcapillary water and protein flux in the liver and intestine of patients with portal-hypertension from hepatic cirrhosis. Gastroenterology 80, 265-272.
78. Gnepp D (1984) Lymphatics. In: Staub N, Taylor AE (eds) Edema. New York: Raven Press, pp. 263-298.
79. Laine GA, Hall JT, Laine SH et al. (1979) Trans-sinusoidal fluiddynamics in canine liver during venous hypertension. Circ Res 45, 317-323.
80. Greenway CV, Lautt WW (1970) Effects of hepatic venous pressure on transsinusoidal fluid transfer in liver of anesthetized cat. Circ Res 26, 697-703.
81. Granger DN, Miller T, Allen R et al. (1979) Permselectivity of cat liver blood-lymph barrier to endogenous macromolecules. Gastroenterology 77, 103-109.
82. Granger DN, Barrowman J (1984) Gastroenterology and liver edema. In: Staub N, Taylor AE (eds) Edema. New York: Raven Press, pp. 615-656.
83. Iber FL (1974) Normal and pathologic physiology of the liver. In: Sodeman W, Sodeman WJ (eds) Pathologic Physiology. Philadelphia: Saunders, pp. 790-817.
84. Freeman S (1953) Recent progress in the physiology and biochemistry of the liver. Med Clin N Am 1, 109-124.
85. Mallet-Guy P, Devic G, Feroldi J et al. (1954) Experimental study of ascites: posthepatic venous stenosis and transposition of the liver into the thorax. Lyon Chir 49, 153-172.
86. Richardson PDI, Granger DN, Mailman D et al. (1980) Permeability characteristics of colonic capillaries. Am J Physiol 239, G300-G-305.
87. Mortillaro NA, Taylor AE (1976) Interaction of capillary and tissue forces in cat small-intestine. Circ Res 39, 348-358.
88. Witte CL, Witte MH, Dumont AE (1980) Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 78, 1059-1068.
89. Huet PM, Goresky CA, Villeneuve JP et al. (1982) Assessment of liver microcirculation in human cirrhosis. J Clin Invest 70, 1234-1244.
90. Vorobioff J, Bredfeldt JE, Groszmann RJ (1984) Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 87, 1120-1126.
91. Buhac I, Jarmolych J (1978) Histology of intestinal peritoneum in patients with cirrhosis of liver and ascites. Am J Dig Dis 23, 417-422.
92. Witte MH, Witte CL, Dumont AE (1971) Progress in liver disease-physiological factors involved in causation of cirrhotic ascites. Gastroenterology 61, 742-750.
93. Witte CL, Witte MH, Cole WR et al. (1969) Dual origin of ascites in hepatic cirrhosis. Surg Gynecol Obstet/Int Abstracts Surg 129, 1027-1033.
94. Vorobioff J, Bredfeldt JE, Groszmann RJ (1983) Hyperdynamic circulation in portal-hypertensive rat model-a primary factor for maintenance of chronic portal-hypertension. Am J Physiol 244, G52-G-57.
95. Bosch J, Enriquez R, Groszmann RJ et al. (1983) Chronic bile-duct ligation in the dog-hemodynamic characterization of a portal hypertensive model. Hepatology 3, 1002-1007.
96. Sugita S, Ohnishi K, Saito M et al. (1987) Splanchnic hemodynamics in portal hypertensive dogs with portal fibrosis. Am J Physiol 252, G748-G-754.
97. Korthuis RJ, Kinden DA, Brimer GE et al. (1988) Intestinal capillary filtration in acute and chronic portal-hypertension. Am J Physiol 254, G339-G-345.
98. Benoit JN, Granger DN (1986) Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 6, 287-298.
99. Kiel JW, Pitts V, Benoit JN et al. (1985) Reduced vascular sensitivity to norepinephrine in portal-hypertensive rats. Am J Physiol 248, G192-G-195.
100. Benoit JN, Korthuis RJ, Granger DN et al. (1990) Splanchnic hemodynamics in acute and chronic portal hypertension. In: Bomzon A, Blendis L (eds) Cardiovascular Complications of Liver Disease. Boca Raton: CRC Press, pp. 179-206.
101. Groszmann RJ (1995) Mechanisms of portal hypertension. In: Arrovo V, Bosch J, Rodes J (eds) Treatments in Hepatology. Barcelona: Masson SA, pp. 3-8.
102. Huet PM, Pomierlayrargues G, Villeneuve JP et al. (1986) Intrahepatic circulation in liver disease. Semin Liver Dis 6, 277-286.
103. Bosch J, Mastai R, Kravetz D et al. (1985) Measurement of azygous venous blood flow in the evaluation of portal hypertension in patients with cirrhosis-clinical and hemodynamic correlations in 100 patients. J Hepatol 1, 125-139.
104. Bosch J, Arroyo V, Betriu A et al. (1980) Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 78, 92-99.
105. Kotelanski B, Groszman R, Cohn JN (1972) Circulation times in splanchnic and hepatic beds in alcoholic liver disease. Gastroenterology 63, 102-111.
106. Arroyo V, Rodes J (1975) Rational approach to treatment of ascites. Postgrad Med J 51, 558-562.
107. Jimenez W, Martinezpardo A, Arroyo V et al. (1985) Temporal relationship between hyper-aldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 5, 245-250.
108. Caregaro L, Lauro S, Angeli P et al. (1985) Renal water and sodium handling in compensated liver-cirrhosis-mechanism of the impaired natriuresis after saline loading. Eur J Clin Invest 15, 360-364.
109. Naccarato R, Messa P, Dangelo A et al. (1981) Renal handling of sodium and water in early chronic liver-disease-evidence for a reduced natriuretic activity of the cirrhotic urinary extracts in rats. Gastroenterology 81, 205-210.
110. Wong F, Massie D, Hsu P et al. (1994) Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology 20, 873-881.
111. Wilkinson SP, Smith IK, Moodie H et al. (1979) Studies on mineralocorticoid escape in cirrhosis. Clin Sci 56, 401-406.
112. Lavilla G, Salmeron JM, Arroyo V et al. (1992) Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 102, 2114-2119.
113. Trevisani F, Bernardi M, Gasbarrini A et al. (1992) Bed-rest-induced hypernatriuresis in cirrhotic-patients without ascites-does it contribute to maintain compensation? J Hepatol 16, 190-196.
114. Bernardi M, Dimarco C, Trevisani F et al. (1993) Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 105, 188-193.
115. Papper S, Rosenbaum JD (1952) Abnormalities in the excretion of water and sodium in compensated cirrhosis of the liver. J Lab Clin Med 40, 523-530.
116. Shear L, Hall PW, Gabuzda GJ (1965) Renal failure in patients with cirrhosis of liver. 2. factors influencing maximal urinary flow rate. Am J Med 39, 199-209.
117. Epstein M (1985) Derangements of renal water handling in liver disease. Gastroenterology 89, 1415-1425.
118. Arroyo V, Rodes J, Gutierrezlizarraga MA et al. (1976) Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 21, 249-256.
119. Rodes J, Brugera M, Teres J et al. (1970) Terminal functional renal insufficiency (TFRI) in liver cirrhosis with ascites. Rev Clin Esp 117, 475-482.
120. Gines A, Escorsell A, Gines P et al. (1993) Incidence, predictive factors, and prognosis of the hepatorenal-syndrome in cirrhosis with ascites. Gastroenterology 105, 229-236.
121. Llach J, Gines P, Arroyo V et al. (1988) Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 94, 482-487.
122. Rodes J, Arroyo V, Bosch J (1975) Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J 51, 492-497.
123. Arroyo V, Gines P, Gerbes AL et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23, 164-176.
124. Laragh J, Sealey JE (1992) Renin-angiotensin-aldosterone system and the regulation of sodium, potassium and blood pressure homeostasis. In: Windhager E (ed.) Handbook of Physiology: Renal Physiology. New York: Oxford University Press, pp. 1409-1542.
125. Simon MA, Diez J, Prieto J (1991) Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. Gastroenterology 101, 1354-1360.
126. Salo J, Gines A, Anibarro L et al. (1995) Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology 22, 479-487.
127. Wilkinson SP, Jowett TP, Slater JDH et al. (1979) Renal sodium retention in cirrhosis-relation to aldosterone and nephron site. Clin Sci 56, 169-177.
128. Perezayuso RM, Arroyo V, Planas R et al. (1983) Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites-relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 84, 961-968.
129. Kotelanski B, Groszman R, Cohn JN (1972) Circulation times in splanchnic and hepatic beds in alcoholic liver disease. Gastroenterology 63, 102-111.
130. Nicholls KM, Shapiro MD, Vanputten VJ et al. (1985) Elevated plasma norepinephrine concentrations in decompensated cirrhosis-association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ Res 56, 457-461.
131. Henriksen J, Ring-Larsen H, Christensen N (1985) Circulating noradrenaline and central haemodynamics in patients with cirrhosis. Scand J Gastroenterol 20, 1185-1190.
132. Lieberman F, Reynolds TB (1967) Plasma volume in cirrhosis of liver-its relation to portal hypertension ascites and renal failure. J Clin Invest 46, 1297-1308.
133. Arroyo V, Bosch J, Mauri M et al. (1981) Effect of angiotensin-II blockade on systemic and hepatic hemodynamics and on the reninangiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 11, 221-229.
134. Perezayuso RM, Arroyo V, Camps J et al. (1984) Renal kallikrein excretion in cirrhotics with ascites-relationship to renal hemodynamics. Hepatology 4, 247-252.
135. Arroyo V, Planas R, Gaya J et al. (1983) Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin-e2 in cirrhosis-relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 13, 271-278.
136. Tobey JC, Weaver LC (1987) Pressoreceptor modulation of renal but not splenic sympathetic reflexes. Am J Physiol 252, R26-R-33.
137. Robertson GL (1992) Regulation of vasopressin secretion. In: Seldin D, Giebisch G (eds) The Kidney: Physiology and Pathophysiology. New York: Raven Press, pp. 1595-1614.
138. Barajas L, Muller J (1973) Innervation of juxtaglomerular apparatus and surrounding tubules-quantitative-analysis by serial section electron microscopy. J Ultrastruct Res 43, 107-132.
139. Kopp U, DiBona G (1992) Neural control of renal function. In: Seldin D, Giebisch G (eds) The Kidney: Physiology and Pathophysiology. New York: Raven Press, pp. 1157-1204.
140. Bichet DG, Vanputten VJ, Schrier RW (1982) Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 307, 1552-1557.
141. Ringlarsen H, Hesse B, Henriksen JH et al. (1982) Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis-plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology 2, 304-310.
142. Maroto A, Gines P, Arroyo V et al. (1993) Brachial and femoral artery blood flow in cirrhosis-relationship to kidney dysfunction. Hepatology 17, 788-793.
143. Solisherruzo JA, Duran A, Favela V et al. (1987) Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 5, 167-173.
144. Ishikawa S, Schrier RW (2003) Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol 58, 1-17.
145. Ishikawa S, Saito T, Kasono K (2004) Pathological role of aquaporin-2 in impaired water excretion and hyponatremia. J Neuroendocrinol 16, 293-296.
146. Jamison R, Gehrig JJ (1992) Urinary concentration and dilution. In: Windhager E (ed.) Handbook of Physiology: Section 8, Renal Physiology. New York: Oxford University Press, pp. 1219-1280.
147. Perezayuso RM, Arroyo V, Camps J et al. (1984) Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 26, 72-80.
148. Linas SL, Anderson RJ, Guggenheim SJ et al. (1981) Role of vasopressin in impaired water-excretion in conscious rats with experimental cirrhosis. Kidney Int 20, 173-180.
149. Claria J, Jimenez W, Arroyo V et al. (1989) Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 97, 1294-1299.
150. Gerbes AL, Golberg V, Gines P et al. (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124, 933-939.
151. Wong F, Blei AT, Blendis LM et al. (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebocontrolled trial. Hepatology 37, 182-191.
152. Gines P, Wong F, Milutinovic S et al. (2006) Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatremia. J Hepatol 44(2), S270.
153. Bosch-Marcé M, Jimenez W, Angeli P et al. (1995) Aquaretic effect of the kappa-opioid agonist Ru-51599 in cirrhotic rats with ascites and water retention. Gastroenterology 109, 217-223.
154. Smith WL (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263, F181-F-191.
155. Schnermann J, Briggs JP (1981) Participation of renal cortical prostaglandins in the regulation of glomerular filtration rate. Kidney Int 19, 802-815.
156. Conrad K, Dunn M (1992) Renal prostaglandins and other eicosanoids. In: Windhager E (ed.) Handbook of Physiology: Section 8, Renal Physiology. New York: Oxford University Press, pp. 1708-1757.
157. Rimola A, Gines P, Arroyo V et al. (1986) Urinary excretion of 6-keto-prostaglandin F1-alpha, thromboxane B-2 and prostaglandin-E2 in cirrhosis with ascites-relationship to functional renal failure (hepatorenal syndrome). J Hepatol 3, 111-117.
158. Moore K, Ward PS, Taylor GW et al. (1991) Systemic and renal production of thromboxane-A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 100, 1069-1077.
159. Boyer TD, Zia P, Reynolds TB (1979) Effect of indomethacin and prostaglandin-A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77, 215-222.
160. Lianos EA, Alavi N, Tobin M et al. (1982) Angiotensin-induced sodium-excretion patterns in cirrhosis-role of renal prostaglandins. Kidney Int 21, 70-77.
161. Wong F, Massie D, Hsu P, Dudley F (1993) Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 104, 869-876.
162. Lianos EA, Alavi N, Tobin M et al. (1982) Angiotensin-induced sodium-excretion patterns in cirrhosis-role of renal prostaglandins. Kidney Int 21, 70-77.
163. Claria J, Kent JD, Lopez-Parra M et al. (2005) Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 41, 579-587.
164. Abelmann WH (1994) Hyperdynamic circulation in cirrhosis-a historical perspective. Hepatology 20, 1356-1358.
165. Fernandez-Seara J, Prieto J, Quiroga J et al. (1989) Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal-failure. Gastroenterology 97, 1304-1312.
166. Guevara M, Bru C, Gines P et al. (1998) Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 28, 39-44.
167. Morales-Ruiz M, Tugues S, Cejudo-Martin P et al. (2005) Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway. J Hepatol 43, 85-91.
168. Wiest R, Das S, Cadelina G et al. (1999) Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 104, 1223-1233.
169. Xu LM, Carter EP, Ohara M et al. (2000) Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol (Renal Physiol) 279, F1110-F-1115.
170. Martin PY, Ohara M, Gines P et al. (1998) Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 101, 235-242.
171. Wiest R, Groszmann RJ (2002) The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35, 478-491.
172. Li Y, Song D, Zhang Y et al. (2003) Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats. Gut 52, 293-299.
173. Gupta S, Morgan TR, Gordan GS (1992) Calcitonin gene-related peptide in hepatorenal-syndrome-a possible mediator of peripheral vasodilation. J Clin Gastroenterol 14, 122-126.
174. Fernandezrodriguez CM, Prieto J, Quiroga J et al. (1995) Plasma levels of substance P in liver cirrhosis-relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology 21, 35-40.
175. Chang CS, Chen GH, Lien HC et al. (1998) Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 28, 1187-1190.
176. Ruiz-del-Arbol L, Monescillo A, Arocena C et al. (2005) Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42, 439-447.
177. Ros J, Claria J, Jimenez W et al. (1995) Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 22, 915-920.
178. Angeli P, Jimenez W, Arroyo V et al. (1994) Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 20, 948-954.
179. Ruiz-del-Arbol W, Urman J, Fernandez J et al. (2003) Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38, 1210-1218.
180. Moller S, Henriksen JH (2002) Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 87, 9-15.
181. Witte CL, Witte MH, Dumont AE (1980) Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 78, 1059-1068.
182. Schrier RW, Arroyo V, Bernardi M et al. (1988) Peripheral arterial vasodilation hypothesis-a proposal for the initiation of renal sodium and water-retention in cirrhosis. Hepatology 8, 1151-1157.
183. Benoit JN, Barrowman JA, Harper SL et al. (1984) Role of humoral factors in the intestinal hyperemia associated with chronic portalhypertension. Am J Physiol 247, G486-G-493.
184. Benoit JN, Granger DN (1988) Intestinal microvascular adaptation to chronic portal hypertension in the rat. Gastroenterology 94, 471-476.
185. Arroyo V, Gines P (1992) Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water-retention in cirrhosis. Gastroenterology 102, 1077-1079.
186. Leak LV, Rahil K (1978) Permeability of diaphragmatic mesothelium-ultrastructural basis for stomata. Am J Anat 151, 557-593.
187. Tsilibary EC, Wissig SL (1977) Absorption from peritoneal-cavity-SEM study of mesothelium covering peritoneal surface of muscular portion of diaphragm. Am J Anat 149, 127-133.
188. Yoffey J, Courtice F (1970) Lymph flow and regional lymphatics. In: Arnold E (ed.) Lymphatics, Lymph and Lymphomyeloid Complex. New York: Academia, pp. 356-443.
189. Buhac I, Flesh L, Kishore R (1984) Intraabdominal pressure and resorption of ascites in decompensated liver cirrhosis. J Lab Clin Med 104, 264-270.
190. Arroyo V, Gines P, Planas R et al. (1986) Management of patients with cirrhosis and ascites. Semin Liver Dis 6, 353-369.
191. Arroyo V, Bosch J, Gayabeltran J et al. (1981) Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 94, 198-201.
192. Tage-Jensen U, Henriksen JH, Christensen E et al. (1988) Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 6, 350-358.
193. Salerno F, Borroni G, Moser P et al. (1993) Survival and prognostic factors of cirrhotic patients with ascites-a study of 134 outpatients. Am J Gastroenterol 88, 514-519.
194. Guardiola J, Xiol X, Escriba JM et al. (1995) Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt. Am J Gastroenterol 90, 2097-2102.
195. Ruf AE, Kremers WK, Chavez LL et al. (2005) Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transplant 11, 336-343.
196. Heuman DM, Abou-assi SG, Habib A et al. (2004) Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 40, 802-810.
197. Schepke M, Roth F, Koch L et al. (2003) Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion 67, 146-153.
198. Borroni G, Maggi A, Sangiovanni A et al. (2000) Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 32, 605-610.
199. Salo J, Guevara M, FernandezEsparrach G et al. (1997) Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems. Hepatology 25, 1338-1342.
200. Gines P, Arrovo V, Rodes J (1992) Pharmacotherapy of ascites associated with cirrhosis. Drugs 43, 316-332.
201. Moore KP, Wong F, Gines P et al. (2003) The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology 38, 258-266.
202. Suki W, Eknoyan G (1992) Physiology of diuretic action. In: Seldin D, Giebisch G (eds) The Kidney: Physiology and Pathophysiology, 2nd edn. New York: Raven, pp. 3629-3670.
203. Puschett J, Winaver J (1992) Effects of diuretics on renal function. In: Windhager E (ed.) Handbook of Physiology: Section 8, Renal Physiology. New York: Oxford University Press, pp. 2335-2407.
204. Karim A (1986) Spironolactone metabolism in man revisited. In: Brumer H (ed.) Contemporary Trends in Diuretic Therapy. Amsterdam: Excerpta Medica, pp. 23-27.
205. Sungaila I, Bartle WR, Walker SE et al. (1992) Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 102, 1680-1685.
206. Sawhney VK, Gregory PB, Swezey SE et al. (1981) Furosemide disposition in cirrhotic patients. Gastroenterology 81, 1012-1016.
207. Pinzani M, Daskalopoulos G, Laffi G et al. (1987) Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology 92, 294-298.
208. Traeger A, Hantze R, Penzlin M et al. (1985) Pharmacokinetics and pharmacodynamic effects of furosemide in patients with liver cirrhosis. Int J Clin Pharmacol Therapeut 23, 129-133.
209. Villeneuve JP, Verbeeck RK, Wilkinson GR et al. (1986) Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Therapeut 40, 14-20.
210. Gatta A, Angeli P, Caregaro L et al. (1991) A pathophysiological interpretation of unresponsiveness to spironolactone in a steppedcare approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 14, 231-236.
211. Bernardi M, Laffi G, Salvagnini M et al. (1993) Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis-a randomized controlled clinical trial comparing 2 diets with different sodium content. Liver 13, 156-162.
212. Forns X, Gines A, Gines P et al. (1994) Management of ascites and renal failure in cirrhosis. Semin Liver Dis 14, 82-96.
213. Santos J, Planas R, Pardo A et al. (2003) Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 39, 187-192.
214. Shear L, Ching S, Gabuzda GJ (1970) Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 282, 1391-&.
215. Sherlock S, Senewira B, Scott A et al. (1966) Complications of diuretic therapy in hepatic cirrhosis. Lancet 1, 1049-1052.
216. Strauss E, de Sa M, Laut C (1985) Standardization of therapeutic approach for ascites due to chronic liver disease. A prospective study of 100 cases. Gastroenterol Endosc Dig 4, 79-86.
217. Angeli P, Albino G, Carraro P et al. (1996) Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 23, 264-273.
218. Lee FY, Lee SD, Tsai YT et al. (1991) A randomized controlled trial of quinidine in the treatment of cirrhotic-patients with muscle cramps. J Hepatol 12, 236-240.
219. Planas R, Arroyo V, Rimola A et al. (1983) Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 84, 247-252.
220. Mirouze D, Zipser RD, Reynolds TB (1983) Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 3, 50-55.
221. Gines P, Arroyo V, Quintero E et al. (1987) Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites-results of a randomized study. Gastroenterology 93, 234-241.
222. Gines P, Tito L, Arroyo V et al. (1988) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94, 1493-1502.
223. Gines A, FernandezEsparrach G, Monescillo A et al. (1996) Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111, 1002-1010.
224. Ruiz-del-Arbol L, Monescillo A, Jimenez W et al. (1997) Paracentesisinduced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 113, 579-586.
225. Sola-Vera J, Minana J, Ricart E et al. (2003) Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 37, 1147-1153.
226. LeVeen HH, Christou G, Ip M et al. (1974) Peritoneo-venous shunting for ascites. Ann Surg 180, 580-591.
227. Fulenwider JT, Galambos JD, Smith RB et al. (1986) Denver peritoneovenous shunts for intractable ascites of cirrhosis-a randomized, prospective trial. Arch Surg 121, 351-355.
228. Schroeder ET, Anderson GH, Smulyan H (1979) Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int 15, 54-61.
229. Smadja C, Franco D (1985) The Leveen shunt in the elective treatment of intractable ascites in cirrhosis-a prospective study on 140 patients. Ann Surg 201, 488-493.
230. Lund RH, Moritz MW (1982) Complications of Denver peritoneovenous shunting. Arch Surg 117, 924-928.
231. Harmon DC, Demirjian Z, Ellman L et al. (1979) Disseminated intravascular coagulation with the peritoneovenous shunt. Ann Intern Med 90, 774-776.
232. Stein SF, Fulenwider JT, Ansley JD et al. (1981) Accelerated fibrinogen and platelet destruction after peritoneovenous shunting. Arch Intern Med 141, 1149-1151.
233. Tang HH, Salem HH, Wood LJ et al. (1992) Coagulopathy during ascites reinfusion-prevention by antiplatelet therapy. Gastroenterology 102, 1334-1339.
234. Ginès A, Planas R, Angeli P et al. (1995) Treatment of patients with cirrhosis and refractory ascites using leveen shunt with titanium tip-comparison with therapeutic paracentesis. Hepatology 22, 124-131.
235. Greenlee HB, Stanley MM, Reinhardt GF (1981) Intractable ascites treated with peritoneovenous shunts (LeVeen)-a 24-month to 64-month follow-up of results in 52 alcoholic cirrhotics. Arch Surg 116, 518-524.
236. Wapnick S, Grosberg SJ, Evans MI (1979) Randomized prospective matched pair study comparing peritoneovenous shunt and conventional therapy in massive ascites. Br J Surg 66, 667-670.
237. Bories P, Garcia Compean D, Michel H et al. (1986) The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J Hepatol 3, 212-218.
238. Ringlarsen H, Siemssen O, Krintel JJ et al. (1988) Diuretic resistant ascites in cirrhosis treated with peritoneo-venous shunt-a randomized controlled trial. Hepatology 8, 1353.
239. Stanley MM, Ochi S, Lee KK et al. (1989) Peritoneovenous shunting as compared with medical-treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 321, 1632-1638.
240. Gines P, Arroyo V, Vargas V et al. (1991) Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 325, 829-835.
241. Orloff MJ (1970) Pathogenesis and surgical treatment of intractable ascites associated with alcoholic cirrhosis. Ann NY Acad Sci 170, 213.
242. Franco D (1983) Treatment of intractable ascites in cirrhotic-patients by portal-systemic shunt. Gastroenterol Clin Biol 7, 533-539.
243. Arrovo V, Cardenas A (1999) TIPS in the treatment of refractory ascites. In: Arrovo V, Bosch J, Bruguera M et al. (eds) Treatment of Liver Diseases. Barcelona: Masson, pp. 43-51.
244. Lebrec D, Giuily N, Hadengue A et al. (1996) Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 25, 135-144.
245. Rossle M, Ochs A, Gulberg V et al. (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342, 1701-1707.
246. Salerno F, Merli M, Riggio O et al. (2004) Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40, 629-635.
247. Gines P, Uriz J, Calahorra B et al. (2002) Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123, 1839-1847.
248. Sanyal AJ, Genning C, Reddy KR et al. (2003) The North American study for the treatment of refractory ascites. Gastroenterology 124, 634-641.
249. Campbell NS, Brensinger CM, Sanyal AJ et al. (2005) Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 42, 635-640.
250. Londono MC, Guevara M, Rimola A et al. (2006) Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 130, 1135-1143.
251. Carrilho F, Bosch J, Arroyo V et al. (1977) Renal failure associated with demeclocycline in cirrhosis. Ann Intern Med 87, 195-197.
252. Perezayuso RM, Arroyo V, Camps J et al. (1984) Effect of demeclocycline on renal-function and urinary prostaglandin-E2 and kallikrein in hyponatremic cirrhotics. Nephron 36, 30-37.
253. Ohnishi A, Orita Y, Okahara R et al. (1993) Potent aquaretic agent-a novel nonpeptide selective vasopressin-2 antagonist (Opc-31260) in men. J Clin Invest 92, 2653-2659.
254. Tsuboi Y, Ishikawa SE, Fujisawa G et al. (1994) Therapeutic efficacy of the nonpeptide AVP antagonist Opc-31260 in cirrhotic rats. Kidney Int 46, 237-244.
255. Bosch-Marcé M, Poo JL, Jimenez W et al. (1999) Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Therapeut 289, 194-201.
256. Jimenez W, Serradeil-Le Gal C, Ros J et al. (2000) Long-term aquaretic efficacy of a selective nonpeptide V-2-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Therapeut 295, 83-90.
257. Fernández-Varol G, Ros J, Cejudo-Martin P et al. (2003) Effect of the V-1a/V-2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 38, 755-761.
258. Inoue T, Ohnishi A, Matsuo A et al. (1998) Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Therapeut 63, 561-570.
259. Guyader D, Patat A, Ellis-Grosse EJ et al. (2002) Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 36, 1197-1205.
260. Wong F, Blei AT, Blendis LM et al. (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebocontrolled trial. Hepatology 37, 182-191.
261. Gerbes AL, Golberg V, Gines P et al. (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124, 933-939.
262. Gadano A, Moreau R, Pessione F et al. (2000) Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 32, 38-42.
263. Cabrera J, Arroyo V, Ballesta AM et al. (1982) Aminoglycoside nephrotoxicity in cirrhosis-value of urinary beta-2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 82, 97-105.
264. Moore RD, Smith CR, Lipsky JJ et al. (1983) Analysis of risk for development of aminoglycoside nephrotoxicity. Clin Res 31, A251.
265. Arroyo V, Perezayuso RM, Camps J et al. (1983) Evidence that renal prostaglandin-E2 (Pge2) plays a major role in the maintenance of water excretion in cirrhosis. Hepatology 3, 856.
266. Zipser RD, Hoefs JC, Speckart PF et al. (1979) Prostaglandins-modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 48, 895-900.
267. Levy M, Wexler MJ, Fechner C (1983) Renal perfusion in dogs with experimental hepatic cirrhosis-role of prostaglandins. Am J Physiol 245, F521-F-529.
268. Bosch-Marce M, Claria J, Titos E et al. (1999) Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 116, 1167-1175.
269. Lopez-Parra M, Claria J, Planaguma A et al. (2002) Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 135, 891-900.
270. Lopez-Parra M, Claria J, Titos E et al. (2005) The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPAR gamma. Influence of albumin. J Hepatol 42, 75-81.
271. Gines A, Salmeron JM, Gines P et al. (1992) Effects of somatostatin on renal function in cirrhosis. Gastroenterology 103, 1868-1874.
272. Mountokalakis T, Kallivretakis N, Mayopoulousymvoulidou D et al. (1988) Enhancement of renal-function by a long-acting somatostatin analog in patients with decompensated cirrhosis. Nephrol Dialys Transplant 3, 604-607.
273. Bernardi M, Depalma R, Trevisani F et al. (1989) Renal function and effective beta-blockade in cirrhosis with ascites-relationship with baseline sympathoadrenergic tone. J Hepatol 8, 279-286.
274. Salmeron JM, Delarbol LR, Gines A et al. (1993) Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 17, 800-806.
275. Salerno F, Borroni G, Lorenzano E et al. (1996) Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients. Hepatology 23, 1135-1140.
276. Vorobioff J, Picabea E, Gamen M et al. (1993) Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients-long-term hemodynamic and renal effects. Hepatology 18, 477-484.
277. Morillas RM, Planas R, Cabre E et al. (1994) Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis-long-term hemodynamic and renal effects. Hepatology 20, 1502-1508.
278. Merkel C, Gatta A, Donada C et al. (1995) Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology 22, 808-813.
279. Albillos A, Lledo JL, Rossi I et al. (1995) Continuous prazosin administration in cirrhotic-patients-effects on portal hemodynamics and on liver and renal function. Gastroenterology 109, 1257-1265.